Identification of low molecular weight degradation merchandise from chitin and chitosan by electrospray ionization time-of-flight mass spectrometry
The useful results offered by chitosan oligosaccharides (COS) make them of curiosity in medical analysis. The monomers that represent COS confer distinct properties, so controlling COS composition throughout their manufacturing is critical.
On this work, we degraded chitin and chitosan polymers and recognized low molecular weight merchandise reminiscent of COS that fashioned, utilizing electrospray ionization time-of-flight mass spectrometry.
Our outcomes present that hydrochloric acid, hydrogen peroxide, and nitrous acid generate distinct merchandise from chitin and chitosan.
Hydrochloric acid degrades chitin and chitosan to supply glucosamine (GlcN) monomers and oligomers. Hydrogen peroxide degrades chitosan to supply GlcN and N-acetyl-d-glucosamine (GlcNAc) monomers and oligomers, and nitrous acid degrades chitosan to supply 2,5-anhydro- d-mannose.
Our research present that COS composition is dictated by each the degradation protocol and the beginning polymer. Moreover, our outcomes allow number of degradation protocols primarily based on their capability to degrade chitin and chitosan and facilitate the manufacturing of COS with desired compositions.
Key phrases: Chitin; Chitosan; Mass spectrometry; Polysaccharide degradation.
allelebio
PSMB8 Antibody |
|||
| BF0434 | Affbiotech | 200ul | EUR 540 |
PSMB8 Antibody |
|||
| 1-CSB-PA775839 | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:2000-1:5000, WB:1:500-1:2000, IHC:1:25-1:100 |
|||
PSMB8 Antibody |
|||
| 1-CSB-PA116429 | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:2000, WB:1:200-1:1000, IHC:1:25-1:100 |
|||
PSMB8 Antibody |
|||
| 1-CSB-PA018886GA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF |
|||
PSMB8 Antibody |
|||
| 1-CSB-PA018886LA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
|||
PSMB8 Conjugated Antibody |
|||
| C43134 | SAB | 100ul | EUR 476.4 |
Anti-PSMB8 antibody |
|||
| STJ11100809 | St John's Laboratory | 100 µl | EUR 495.6 |
|
Description: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit. |
|||
Anti-PSMB8 antibody |
|||
| STJ29479 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit. |
|||
PSMB8 Polyclonal Antibody |
|||
| A73468-050 | EpiGentek | 50 ul | EUR 377.3 |
PSMB8 Polyclonal Antibody |
|||
| A73468-100 | EpiGentek | 100 ul | EUR 577.5 |
PSMB8 Polyclonal Antibody |
|||
| A73468 | EpiGentek |
|
|
Psmb8/ Rat Psmb8 ELISA Kit |
|||
| ELI-15652r | Lifescience Market | 96 Tests | EUR 1063.2 |
PSMB8 siRNA |
|||
| 20-abx904317 | Abbexa |
|
|
PSMB8 siRNA |
|||
| 20-abx930156 | Abbexa |
|
|
PSMB8 siRNA |
|||
| 20-abx930157 | Abbexa |
|
|
pOTB7-PSMB8 |
|||
| PVT18497 | Lifescience Market | 2 ug | EUR 277.2 |
PSMB8 Antibody, HRP conjugated |
|||
| 1-CSB-PA018886LB01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
|||
PSMB8 Antibody, FITC conjugated |
|||
| 1-CSB-PA018886LC01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
|||
PSMB8 Antibody, Biotin conjugated |
|||
| 1-CSB-PA018886LD01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
|||
PSMB8 Rabbit pAb |
|||
| A7340-100ul | Abclonal | 100 ul | EUR 369.6 |
PSMB8 Rabbit pAb |
|||
| A7340-200ul | Abclonal | 200 ul | EUR 550.8 |
PSMB8 Rabbit pAb |
|||
| A7340-20ul | Abclonal | 20 ul | EUR 219.6 |
PSMB8 Rabbit pAb |
|||
| A7340-50ul | Abclonal | 50 ul | EUR 267.6 |
PSMB8 Blocking Peptide |
|||
| BF0434-BP | Affbiotech | 1mg | EUR 234 |
anti-PSMB8 (1A5) |
|||
| LF-MA30618 | Abfrontier | 100 ul | EUR 632.4 |
|
Description: Mouse Monoclonal to PSMB8 |
|||
Monoclonal PSMB8 Antibody, Clone: 1A5 |
|||
| AMM02864G | Leading Biology | 0.1ml | EUR 633.6 |
|
Description: A Monoclonal antibody against Human PSMB8. The antibodies are raised in Mouse and are from clone 1A5. This antibody is applicable in WB and IHC, ICC, E |
|||
Anti-PSMB8 / LMP7 Monoclonal Antibody |
|||
| M02188-2 | BosterBio | 100ug | EUR 476.4 |
|
Description: Rabbit Monoclonal PSMB8 / LMP7 Antibody. Validated in IP, IF, WB and tested in Human, Mouse, Rat. |
|||
PSMB8 protein (His tag) |
|||
| 80R-2608 | Fitzgerald | 100 ug | EUR 386.4 |
|
Description: Purified recombinant PSMB8 protein |
|||
Human PSMB8 shRNA Plasmid |
|||
| 20-abx953843 | Abbexa |
|
|
Rat PSMB8 shRNA Plasmid |
|||
| 20-abx984734 | Abbexa |
|
|
Mouse PSMB8 shRNA Plasmid |
|||
| 20-abx971337 | Abbexa |
|
|
Canine PSMB8 ELISA KIT |
|||
| ELI-15651d | Lifescience Market | 96 Tests | EUR 1113.6 |
PSMB8 Recombinant Protein (Rat) |
|||
| RP222629 | ABM | 100 ug | Ask for price |
PSMB8 Recombinant Protein (Human) |
|||
| RP085356 | ABM | 100 ug | Ask for price |
PSMB8 Recombinant Protein (Mouse) |
|||
| RP165287 | ABM | 100 ug | Ask for price |
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| 20-abx141396 | Abbexa |
|
|
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| 20-abx006453 | Abbexa |
|
|
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| 20-abx114776 | Abbexa |
|
|
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| abx011689-100ul | Abbexa | 100 ul | EUR 493.2 |
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| abx028154-400ul | Abbexa | 400 ul | EUR 627.6 |
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| abx028154-80l | Abbexa | 80 µl | EUR 343.2 |
Proteasome subunit beta type-8 (PSMB8) Antibody |
|||
| 20-abx211178 | Abbexa |
|
|
Proteasome subunit beta type-8 (PSMB8) Antibody |
|||
| 20-abx211851 | Abbexa |
|
|
Monoclonal PSMB8 Antibody (monoclonal) (M01), Clone: 1B3 |
|||
| AMM03954G | Leading Biology | 0.1mg | EUR 580.8 |
|
Description: A Monoclonal antibody against Human PSMB8 (monoclonal) (M01). The antibodies are raised in Mouse and are from clone 1B3. This antibody is applicable in WB, IHC and IF, IP, E |
|||
[KO Validated] PSMB8 Rabbit pAb |
|||
| A19933-100ul | Abclonal | 100 ul | EUR 492 |
[KO Validated] PSMB8 Rabbit pAb |
|||
| A19933-200ul | Abclonal | 200 ul | EUR 685.2 |
[KO Validated] PSMB8 Rabbit pAb |
|||
| A19933-20ul | Abclonal | 20 ul | EUR 265.2 |
[KO Validated] PSMB8 Rabbit pAb |
|||
| A19933-50ul | Abclonal | 50 ul | EUR 344.4 |
PSMB8 ELISA Kit (Human) (OKEH07770) |
|||
| OKEH07770 | Aviva Systems Biology | 96 Wells | EUR 1310.4 |
|
Description: Description of target: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit.;Species reactivity: Human;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.06ng/mL |
|||
Psmb8 ORF Vector (Mouse) (pORF) |
|||
| ORF055097 | ABM | 1.0 ug DNA | EUR 607.2 |
Psmb8 ORF Vector (Rat) (pORF) |
|||
| ORF074211 | ABM | 1.0 ug DNA | EUR 607.2 |
PSMB8 ELISA Kit (Dog) (OKEH03975) |
|||
| OKEH03975 | Aviva Systems Biology | 96 Wells | EUR 1012.8 |
|
Description: Description of target: ;Species reactivity: Dog;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.064 ng/mL |
|||
PSMB8 ELISA Kit (Human) (OKCD02695) |
|||
| OKCD02695 | Aviva Systems Biology | 96 Wells | EUR 950.4 |
|
Description: Description of target: The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB5 by PSMB8 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Acts as a major component of interferon gamma-induced sensitivity. Plays a key role in apoptosis via the degradation of the apoptotic inhibitor MCL1. May be involved in the inflammatory response pathway. In cancer cells, substitution of isoform 1 (E2) by isoform 2 (E1) results in immunoproteasome deficiency. Required for the differentiation of preadipocytes into adipocytes.;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.117 ng/mL |
|||
PSMB8 ORF Vector (Human) (pORF) |
|||
| ORF028453 | ABM | 1.0 ug DNA | EUR 486 |
Psmb8 sgRNA CRISPR Lentivector set (Rat) |
|||
| K6921501 | ABM | 3 x 1.0 ug | EUR 406.8 |
PSMB8 sgRNA CRISPR Lentivector set (Human) |
|||
| K1740301 | ABM | 3 x 1.0 ug | EUR 406.8 |
Psmb8 sgRNA CRISPR Lentivector set (Mouse) |
|||
| K4425601 | ABM | 3 x 1.0 ug | EUR 406.8 |
Human Proteasome subunit beta type-8 (PSMB8) |
|||
| 1-CSB-EP018886HU | Cusabio |
|
|
|
Description: Recombinant Human Proteasome subunit beta type-8(PSMB8) expressed in E.coli |
|||
Psmb8 sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K6921502 | ABM | 1.0 ug DNA | EUR 184.8 |
Psmb8 sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K6921503 | ABM | 1.0 ug DNA | EUR 184.8 |
Psmb8 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K6921504 | ABM | 1.0 ug DNA | EUR 184.8 |
PSMB8 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K1740302 | ABM | 1.0 ug DNA | EUR 184.8 |
PSMB8 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K1740303 | ABM | 1.0 ug DNA | EUR 184.8 |
PSMB8 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K1740304 | ABM | 1.0 ug DNA | EUR 184.8 |
Psmb8 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K4425602 | ABM | 1.0 ug DNA | EUR 184.8 |
Psmb8 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K4425603 | ABM | 1.0 ug DNA | EUR 184.8 |
Psmb8 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K4425604 | ABM | 1.0 ug DNA | EUR 184.8 |
PSMB8 Protein Vector (Human) (pPB-C-His) |
|||
| PV113810 | ABM | 500 ng | EUR 662.4 |
PSMB8 Protein Vector (Human) (pPB-N-His) |
|||
| PV113811 | ABM | 500 ng | EUR 662.4 |
PSMB8 Protein Vector (Human) (pPM-C-HA) |
|||
| PV113812 | ABM | 500 ng | EUR 662.4 |
PSMB8 Protein Vector (Human) (pPM-C-His) |
|||
| PV113813 | ABM | 500 ng | EUR 662.4 |
PSMB8 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV220386 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV220387 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV220388 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV220389 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Rat) (pPB-C-His) |
|||
| PV296842 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Rat) (pPB-N-His) |
|||
| PV296843 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Rat) (pPM-C-HA) |
|||
| PV296844 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Rat) (pPM-C-His) |
|||
| PV296845 | ABM | 500 ng | EUR 723.6 |
Molecular docking and dynamics simulations research of OmpATb identifies 4 potential novel pure product-derived anti-Mycobacterium tuberculosis compounds
The outer membrane protein A (OmpATb) of Mycobacterium tuberculosis is a virulence issue that neutralizes the host pH to impede the uptake of hydrophilic antitubercular medication. Figuring out pure compounds with the potential to inhibit OmpATb might enable circumvention of the porin-like actions of OmpATb. 4 potential leads comprising ZINC000003958185, ZINC000000157405, ZINC000000001392 and ZINC000034268676 had been obtained by digital screening of 6394 numerous pure merchandise.
Characterization of the binding interactions of the potential leads with OmpATb revealed 9 crucial residues comprising ARG86, LEU110, LEU113, LEU114, ALA115, PHE142, SER145, VAL146, and PHE151. Molecular dynamics simulations additionally revealed very steady protein-lead complexes. Most residues contributed decrease binding energies to the general molecular mechanics Poisson-Boltzmann floor space (MM-PBSA) binding free energies of the interactions between the molecules and OmpATb protein.
Induced Match Docking (IFD) of the compounds regenerated poses of the molecular docking utilizing AutoDock Vina. These molecules might be beginning templates for designing inhibitors to bypass the pore mediating actions of OmpATb. Based mostly on structural similarity, ZINC000034268676 was urged as a possible scaffold for designing efflux pump inhibitors of the gate mediating actions of OmpATb and will improve the uptake of hydrophilic medication to cut back the period time of tuberculosis therapy.
Moreover, structurally comparable compounds out there within the DrugBank database with a similarity threshold of 0.7 have been reported to exhibit antitubercular and anti-mycobacterial actions. These biomolecules might be additional characterised experimentally to corroborate their antitubercular exercise. Additionally, the skeletons of the molecules might be adopted as sub-structures for the design of future anti-mycobacterial medication.
Key phrases: Antitubercular compounds; Induced-fit docking; MM-PBSA; Molecular docking; Molecular dynamics; Mycobacterium tuberculosis OmpATb; Pure merchandise; Digital screening
Placing the Brakes on Tumorigenesis with Pure Merchandise of Plant Origin: Insights into the Molecular Mechanisms of Actions and Immune Targets for Bladder Most cancers Remedy.
Bladder most cancers is the 10th mostly identified most cancers worldwide. Though the incidence in males is four instances larger than that in ladies, the diagnoses are worse for ladies.
Over the previous 30 years, the therapy for bladder most cancers has not achieved a major optimistic impact, and the outlook for mortality charges resulting from muscle-invasive bladder most cancers and metastatic illness isn’t optimistic. Phytochemicals present in crops and their derivatives current promising potentialities for most cancers remedy with improved therapy results and decreased toxicity.
On this examine, we summarize the promising pure merchandise of plant origin with anti-bladder most cancers potential, and their anticancer mechanisms-especially apoptotic induction-are mentioned.
With the developments in immunotherapy, small-molecule focused immunotherapy has been promoted as a passable strategy, and the invention of novel small molecules towards immune targets for bladder most cancers therapy from merchandise of plant origin represents a promising avenue of analysis. It’s our hope that this might pave the way in which for brand spanking new concepts within the fields of oncology, immunology, phytochemistry, and cell biology, using pure merchandise of plant origin as promising medication for bladder most cancers therapy
PSMB8 Antibody |
|||
| BF0434 | Affbiotech | 200ul | EUR 540 |
PSMB8 Antibody |
|||
| 1-CSB-PA775839 | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:2000-1:5000, WB:1:500-1:2000, IHC:1:25-1:100 |
|||
PSMB8 Antibody |
|||
| 1-CSB-PA116429 | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:2000, WB:1:200-1:1000, IHC:1:25-1:100 |
|||
PSMB8 Antibody |
|||
| 1-CSB-PA018886GA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF |
|||
PSMB8 Antibody |
|||
| 1-CSB-PA018886LA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
|||
PSMB8 Conjugated Antibody |
|||
| C43134 | SAB | 100ul | EUR 476.4 |
Anti-PSMB8 antibody |
|||
| STJ11100809 | St John's Laboratory | 100 µl | EUR 495.6 |
|
Description: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit. |
|||
Anti-PSMB8 antibody |
|||
| STJ29479 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit. |
|||
PSMB8 Polyclonal Antibody |
|||
| A73468-050 | EpiGentek | 50 ul | EUR 377.3 |
PSMB8 Polyclonal Antibody |
|||
| A73468-100 | EpiGentek | 100 ul | EUR 577.5 |
PSMB8 Polyclonal Antibody |
|||
| A73468 | EpiGentek |
|
|
Psmb8/ Rat Psmb8 ELISA Kit |
|||
| ELI-15652r | Lifescience Market | 96 Tests | EUR 1063.2 |
PSMB8 siRNA |
|||
| 20-abx904317 | Abbexa |
|
|
PSMB8 siRNA |
|||
| 20-abx930156 | Abbexa |
|
|
PSMB8 siRNA |
|||
| 20-abx930157 | Abbexa |
|
|
pOTB7-PSMB8 |
|||
| PVT18497 | Lifescience Market | 2 ug | EUR 277.2 |
PSMB8 Antibody, HRP conjugated |
|||
| 1-CSB-PA018886LB01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
|||
PSMB8 Antibody, FITC conjugated |
|||
| 1-CSB-PA018886LC01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
|||
PSMB8 Antibody, Biotin conjugated |
|||
| 1-CSB-PA018886LD01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
|||
PSMB8 Rabbit pAb |
|||
| A7340-100ul | Abclonal | 100 ul | EUR 369.6 |
PSMB8 Rabbit pAb |
|||
| A7340-200ul | Abclonal | 200 ul | EUR 550.8 |
PSMB8 Rabbit pAb |
|||
| A7340-20ul | Abclonal | 20 ul | EUR 219.6 |
PSMB8 Rabbit pAb |
|||
| A7340-50ul | Abclonal | 50 ul | EUR 267.6 |
PSMB8 Blocking Peptide |
|||
| BF0434-BP | Affbiotech | 1mg | EUR 234 |
anti-PSMB8 (1A5) |
|||
| LF-MA30618 | Abfrontier | 100 ul | EUR 632.4 |
|
Description: Mouse Monoclonal to PSMB8 |
|||
Monoclonal PSMB8 Antibody, Clone: 1A5 |
|||
| AMM02864G | Leading Biology | 0.1ml | EUR 633.6 |
|
Description: A Monoclonal antibody against Human PSMB8. The antibodies are raised in Mouse and are from clone 1A5. This antibody is applicable in WB and IHC, ICC, E |
|||
Anti-PSMB8 / LMP7 Monoclonal Antibody |
|||
| M02188-2 | BosterBio | 100ug | EUR 476.4 |
|
Description: Rabbit Monoclonal PSMB8 / LMP7 Antibody. Validated in IP, IF, WB and tested in Human, Mouse, Rat. |
|||
PSMB8 protein (His tag) |
|||
| 80R-2608 | Fitzgerald | 100 ug | EUR 386.4 |
|
Description: Purified recombinant PSMB8 protein |
|||
Human PSMB8 shRNA Plasmid |
|||
| 20-abx953843 | Abbexa |
|
|
Rat PSMB8 shRNA Plasmid |
|||
| 20-abx984734 | Abbexa |
|
|
Mouse PSMB8 shRNA Plasmid |
|||
| 20-abx971337 | Abbexa |
|
|
Canine PSMB8 ELISA KIT |
|||
| ELI-15651d | Lifescience Market | 96 Tests | EUR 1113.6 |
PSMB8 Recombinant Protein (Rat) |
|||
| RP222629 | ABM | 100 ug | Ask for price |
PSMB8 Recombinant Protein (Human) |
|||
| RP085356 | ABM | 100 ug | Ask for price |
PSMB8 Recombinant Protein (Mouse) |
|||
| RP165287 | ABM | 100 ug | Ask for price |
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| 20-abx141396 | Abbexa |
|
|
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| 20-abx006453 | Abbexa |
|
|
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| 20-abx114776 | Abbexa |
|
|
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| abx011689-100ul | Abbexa | 100 ul | EUR 493.2 |
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| abx028154-400ul | Abbexa | 400 ul | EUR 627.6 |
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| abx028154-80l | Abbexa | 80 µl | EUR 343.2 |
Proteasome subunit beta type-8 (PSMB8) Antibody |
|||
| 20-abx211178 | Abbexa |
|
|
Proteasome subunit beta type-8 (PSMB8) Antibody |
|||
| 20-abx211851 | Abbexa |
|
|
Monoclonal PSMB8 Antibody (monoclonal) (M01), Clone: 1B3 |
|||
| AMM03954G | Leading Biology | 0.1mg | EUR 580.8 |
|
Description: A Monoclonal antibody against Human PSMB8 (monoclonal) (M01). The antibodies are raised in Mouse and are from clone 1B3. This antibody is applicable in WB, IHC and IF, IP, E |
|||
[KO Validated] PSMB8 Rabbit pAb |
|||
| A19933-100ul | Abclonal | 100 ul | EUR 492 |
[KO Validated] PSMB8 Rabbit pAb |
|||
| A19933-200ul | Abclonal | 200 ul | EUR 685.2 |
[KO Validated] PSMB8 Rabbit pAb |
|||
| A19933-20ul | Abclonal | 20 ul | EUR 265.2 |
[KO Validated] PSMB8 Rabbit pAb |
|||
| A19933-50ul | Abclonal | 50 ul | EUR 344.4 |
PSMB8 ELISA Kit (Human) (OKEH07770) |
|||
| OKEH07770 | Aviva Systems Biology | 96 Wells | EUR 1310.4 |
|
Description: Description of target: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit.;Species reactivity: Human;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.06ng/mL |
|||
Psmb8 ORF Vector (Mouse) (pORF) |
|||
| ORF055097 | ABM | 1.0 ug DNA | EUR 607.2 |
Psmb8 ORF Vector (Rat) (pORF) |
|||
| ORF074211 | ABM | 1.0 ug DNA | EUR 607.2 |
PSMB8 ELISA Kit (Dog) (OKEH03975) |
|||
| OKEH03975 | Aviva Systems Biology | 96 Wells | EUR 1012.8 |
|
Description: Description of target: ;Species reactivity: Dog;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.064 ng/mL |
|||
PSMB8 ELISA Kit (Human) (OKCD02695) |
|||
| OKCD02695 | Aviva Systems Biology | 96 Wells | EUR 950.4 |
|
Description: Description of target: The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB5 by PSMB8 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Acts as a major component of interferon gamma-induced sensitivity. Plays a key role in apoptosis via the degradation of the apoptotic inhibitor MCL1. May be involved in the inflammatory response pathway. In cancer cells, substitution of isoform 1 (E2) by isoform 2 (E1) results in immunoproteasome deficiency. Required for the differentiation of preadipocytes into adipocytes.;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.117 ng/mL |
|||
PSMB8 ORF Vector (Human) (pORF) |
|||
| ORF028453 | ABM | 1.0 ug DNA | EUR 486 |
Psmb8 sgRNA CRISPR Lentivector set (Rat) |
|||
| K6921501 | ABM | 3 x 1.0 ug | EUR 406.8 |
PSMB8 sgRNA CRISPR Lentivector set (Human) |
|||
| K1740301 | ABM | 3 x 1.0 ug | EUR 406.8 |
Psmb8 sgRNA CRISPR Lentivector set (Mouse) |
|||
| K4425601 | ABM | 3 x 1.0 ug | EUR 406.8 |
Human Proteasome subunit beta type-8 (PSMB8) |
|||
| 1-CSB-EP018886HU | Cusabio |
|
|
|
Description: Recombinant Human Proteasome subunit beta type-8(PSMB8) expressed in E.coli |
|||
Psmb8 sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K6921502 | ABM | 1.0 ug DNA | EUR 184.8 |
Psmb8 sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K6921503 | ABM | 1.0 ug DNA | EUR 184.8 |
Psmb8 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K6921504 | ABM | 1.0 ug DNA | EUR 184.8 |
PSMB8 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K1740302 | ABM | 1.0 ug DNA | EUR 184.8 |
PSMB8 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K1740303 | ABM | 1.0 ug DNA | EUR 184.8 |
PSMB8 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K1740304 | ABM | 1.0 ug DNA | EUR 184.8 |
Psmb8 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K4425602 | ABM | 1.0 ug DNA | EUR 184.8 |
Psmb8 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K4425603 | ABM | 1.0 ug DNA | EUR 184.8 |
Psmb8 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K4425604 | ABM | 1.0 ug DNA | EUR 184.8 |
PSMB8 Protein Vector (Human) (pPB-C-His) |
|||
| PV113810 | ABM | 500 ng | EUR 662.4 |
PSMB8 Protein Vector (Human) (pPB-N-His) |
|||
| PV113811 | ABM | 500 ng | EUR 662.4 |
PSMB8 Protein Vector (Human) (pPM-C-HA) |
|||
| PV113812 | ABM | 500 ng | EUR 662.4 |
PSMB8 Protein Vector (Human) (pPM-C-His) |
|||
| PV113813 | ABM | 500 ng | EUR 662.4 |
PSMB8 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV220386 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV220387 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV220388 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV220389 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Rat) (pPB-C-His) |
|||
| PV296842 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Rat) (pPB-N-His) |
|||
| PV296843 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Rat) (pPM-C-HA) |
|||
| PV296844 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Rat) (pPM-C-His) |
|||
| PV296845 | ABM | 500 ng | EUR 723.6 |